Bozeman, Montana (September 14, 2005) - Golden Helix, Inc. announced today that its HelixTree® application has achieved GeneChip-compatible™ status with the Affymetrix Inc. (Nasdaq: AFFX) microarray platform and that it has joined the Affymetrix GeneChip-compatible Applications Program, which provides customers with a broad spectrum of software solutions for biomedical research and development. As a GeneChip-compatible Software provider, Golden Helix is committed to seamlessly integrating its HelixTree® Genetics Analysis Software with the Affymetrix technology.
HelixTree® Genetics Analysis Software was developed in collaboration with leading researchers in the fields of genetics and statistics at GlaxoSmithKline, NIH and the University of Minnesota to effectively elucidate complex relationships among genetic variations, environmental factors, disease status and clinical outcomes. With the advent of whole-genome association studies, HelixTree® was designed to analyze very large data sets on a desktop computer. It offers advanced genetics analysis tools, an intuitive and interactive user-interface and a complete programmatic scripting language making it a popular genetics analysis package for expert and novice researchers alike.
“It is apparent that despite the vast number of analysis packages available, analysis of large data sets and interpretability of results are still real challenges that scientists face,” stated Dr. Christophe Lambert, President and CEO of Golden Helix. “Collaborating with Affymetrix to overcome these challenges has been rewarding for us and our customers.”
“With the recent launch of the Affymetrix GeneChip Human Mapping 500K Array Set, whole-genome association studies are now practical and affordable. As the technology continues to advance, it is important that we provide our customers with a broad spectrum of user-friendly analysis tools, such as HelixTree® Genetics Analysis Software,” said Steve Lincoln, Vice President of Informatics at Affymetrix. “We look forward to continuing our relationship with Golden Helix to help address these emerging needs.”
About the Affymetrix Developers Network (ADN)
Through one of the largest third-party software developer communities within the life science industry, Affymetrix works with its partners to provide a broad spectrum of solutions for leveraging gene expression and genetic variation analysis in both biomedical research and development. Membership in ADN is free of charge for both commercial and academic software developers. For more information please visit www.affymetrix.com/genechip/developer. Visit the GeneChip-compatible Software Solutions Catalog at www.affymetrix.com/genechip/compatible.
Affymetrix scientists invented the world's first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip® technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,200 systems have been shipped around the world and more than 3,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyze the relationship between genetics and health. Headquartered in Santa Clara, Calif., Affymetrix has subsidiaries in Europe and Asia in addition to manufacturing facilities in Sacramento, Calif. and Bedford, Mass. The company has about 900 employees worldwide. For more information about Affymetrix, please visit the company's web site at http://www.affymetrix.com
About Golden Helix, Inc.
Founded in 1998 in Bozeman, MT, Golden Helix is a leading provider of data analysis software products and services designed to accelerate life science research and increase pharmaceutical R&D productivity. The company's products enable hundreds of researchers at the world's top pharmaceutical, biotech and non-profit research organizations to discover the genes that cause disease, improve target and lead discovery processes, and advance pharmacogenetic initiatives. Its products have been cited in nearly 100 peer reviewed publications that detail ground-breaking research for discovering the genetic and environmental basis of disease and creating safer and more effective medicines.
Golden Helix is committed to Accelerating the Quest for Significance.
For more information, please visit www.goldenhelix.com.
Director of Marketing
Golden Helix, Inc.